avatrombopag: enhances megakaryocytopoiesis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9852519 |
| CHEMBL ID | 2103883 |
| SCHEMBL ID | 289354 |
| MeSH ID | M0527096 |
| Synonym |
|---|
| D10306 |
| avatrombopag (usan/inn) |
| unii-3h8gsz4sql |
| akr 501 |
| 3h8gsz4sql , |
| 1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid |
| as 1670542 |
| 570406-98-3 |
| 4-piperidinecarboxylic acid, 1-(3-chloro-5-(((4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl)amino)carbonyl)-2-pyridinyl)- |
| e5501 |
| avatrombopag [usan:inn] |
| ym477 |
| avatrombopag |
| e 5501 |
| e5501 compound |
| akr501 |
| ym 477 |
| doptelet |
| e-5501 |
| akr-501 |
| ym-477 |
| CHEMBL2103883 |
| ym-301477 |
| 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl)piperidine-4-carboxylic acid |
| avatrombopag [who-dd] |
| 1-(3-chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid |
| avatrombopag [inn] |
| avatrombopag [mi] |
| avatrombopag [usan] |
| S6624 |
| SCHEMBL289354 |
| 1-[3-chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]-4-piperidinecarboxylic acid |
| CS-3397 |
| 1-(3-chloro-5-((4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)pyridin-2-yl)piperidine-4-carboxylic acid |
| HY-13463 |
| DTXSID30205667 , |
| AKOS027323962 |
| DB11995 |
| FT-0728753 |
| BCP28031 |
| gtpl9953 |
| 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid |
| SB16846 |
| AMY40535 |
| e5501;akr-501;ym477 |
| Q27257213 |
| F85065 |
| MS-30955 |
| 570406-98-3 (free base) |
| avatrombopag free base |
| (1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid) |
| VXA40698 |
| EN300-18167306 |
| 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl}pyridin-2-yl)piperidine-4-carboxylic acid |
| b02bx08 |
| avatrombopagum |
| dtxcid60128158 |
| EX-A6599 |
| akr-501;e5501;ym477 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Following single dosing under fasted and fed conditions, mean peak concentrations occurred at 5 to 8 hours and subsequently declined with a half-life of 16 to 18 hours in Japanese and white subjects." | ( Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects. Aluri, J; Ferry, J; Han, D; Nomoto, M; Pastino, G; Rege, B, 2018) | 0.48 |
| "16-fold increase of AUC of avatrombopag, prolonged terminal elimination phase half-life (from 19." | ( Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Aluri, J; Boyd, P; Chang, MK; Ferry, J; Lai, WG; Nomoto, M; Rege, B; Schuck, E; Siu, YA; Yasuda, S; Zamora, CA, 2018) | 0.48 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Here, we report that AKR-501 in combination with TPO has additive effect on megakaryocytopoiesis." | ( AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis. Abe, M; Fukushima-Shintani, M; Hirayama, F; Iwatsuki, Y; Kawasaki, T; Sugasawa, K; Suzuki, K, 2008) | 0.35 |
| " We assessed three drug-drug interactions of avatrombopag as a victim with dual or selective CYP2C9/3A inhibitors and inducers." | ( Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. Aluri, J; Boyd, P; Chang, MK; Ferry, J; Lai, WG; Nomoto, M; Rege, B; Schuck, E; Siu, YA; Yasuda, S; Zamora, CA, 2018) | 0.48 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Following single dosing under fasted and fed conditions, mean peak concentrations occurred at 5 to 8 hours and subsequently declined with a half-life of 16 to 18 hours in Japanese and white subjects." | ( Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects. Aluri, J; Ferry, J; Han, D; Nomoto, M; Pastino, G; Rege, B, 2018) | 0.48 |
| " Chemical structures, available dosage forms, recommended dosing, pharmacokinetics, results of toxicity studies in animals, most frequent adverse effects, significant outcomes of the corresponding clinical trials, and their use in specific patient populations are thoroughly described." | ( New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations. Al-Horani, RA; Clemons Bankston, P, 2019) | 0.51 |
| " Although TPO-RAs are often selected as treatments for chronic ITP, when choosing between the TPO-RAs, clinicians must balance safety profile, dosing restrictions, and method of administration incorporating patient preference." | ( An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia. Al-Samkari, H; Song, AB, 2022) | 0.72 |
| "Compared with other TPO-RAs used to treat ITP, avatrombopag offers practical oral dosing with a single pill strength, does not require long-term dietary restrictions, and has no warning for hepatotoxicity." | ( An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia. Al-Samkari, H; Song, AB, 2022) | 0.72 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (5.56) | 29.6817 |
| 2010's | 19 (35.19) | 24.3611 |
| 2020's | 32 (59.26) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.62) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 11 (20.00%) | 5.53% |
| Reviews | 17 (30.91%) | 6.00% |
| Case Studies | 7 (12.73%) | 4.05% |
| Observational | 1 (1.82%) | 0.25% |
| Other | 19 (34.55%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||